Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + Nivolumab in Chinese Participants with Advanced Solid Tumors
NCT05498480Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of relatlimab in solid tumor (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants with Adverse Events (AEs) up to 123 Weeks, Number of Participants with Immune-mediated Adverse Events (IMAEs) up to 123 Weeks and 8 more. Started Jul 2022; status: completed.
02
Drugs
relatlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05498480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498480.